RJFSA
PRTK

Raymond James Financial Services Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Raymond James Financial Services Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14,202
Closed -$77K – 3113
2020
Q3 		$77K Buy
+14,202
New +$70.3K ﹤0.01% 2727
2020
Q1 		– Sell
-11,217
Closed -$45K – 2911
2019
Q4 		$45K Buy
11,217
+100
+0.9% +$347 ﹤0.01% 2767
2019
Q3 		$48K Sell
11,117
-3,000
-21% -$12K ﹤0.01% 2702
2019
Q2 		$56K Sell
14,117
-4,750
-25% -$22.6K ﹤0.01% 2734
2019
Q1 		$101K Buy
18,867
+2,500
+15% +$16.1K ﹤0.01% 2644
2018
Q4 		$84K Sell
16,367
-900
-5% -$6.83K ﹤0.01% 2419
2018
Q3 		$167K Sell
17,267
-350
-2% -$3.53K ﹤0.01% 2579
2018
Q2 		$180K Buy
17,617
+500
+3% +$5.66K ﹤0.01% 2514
2018
Q1 		$223K Buy
+17,117
New +$255K ﹤0.01% 2195
2017
Q4 		– Sell
-11,133
Closed -$279K – 2735
2017
Q3 		$279K Buy
+11,133
New +$259K ﹤0.01% 2066

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial Services Advisors's PRTK Position: Q4 2020 in Review

Raymond James Financial Services Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2020, closing a stake of 14,202 shares — an estimated $77K sold.

Raymond James Financial Services Advisors first reported a position in PRTK in Q3 2017 and held it in 10 quarters. The position peaked at $279K in Q3 2017. 108 funds tracked by Wall St. Rank hold PRTK as of Q4 2020.

  • Raymond James Financial Services Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 14,202 Paratek Pharmaceuticals, Inc. shares in Q4 2020, an estimated $77K.
  • Raymond James Financial Services Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and held it in 10 quarters.
  • Raymond James Financial Services Advisors's Paratek Pharmaceuticals, Inc. position peaked at $279K in Q3 2017.
  • 108 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.